“We are desperately in need of new therapies for patients with AML and MDS. Phase I clinical trials in this disease space are instrumental and also extremely challenging. The quicker these trials can be opened and enrolled, the quicker we achieve our goals of finding more effective and safer ways to treat these deadly diseases. CATALIS allowed us to open this trial in 8.6 weeks and we enrolled the second patient worldwide. The JGH CRU is a Canadian leader in phase I studies, CATALIS is now part of how we ensure our success and how we get promising therapies to Quebec and Canadian patients so quickly.”
